Evolent Health (EVH) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue was $483.6M, at the high end of expectations but down year-over-year due to contract transitions and scope changes; strong organic growth and five new revenue agreements signed, adding about $10M in annualized revenue and expanding reach to over 1 million new lives.

• Net loss attributable to common shareholders was $72.3M, compared to $25.2M in Q1 2024, driven by lower revenue, a $52.3M loss on option exercise, and higher interest expense.

• Oncology navigation solution officially launched, integrating proprietary protocols, acquired assets, and digital tools, targeting over 300,000 members.

• Continued scaling of oncology management and AI-based automation initiatives, including the Machinify acquisition.

• The 2023 Repositioning Plan concluded in Q2 2024, streamlining operations and reducing costs.

Financial highlights

• Q1 2025 revenue was $483.6M, impacted by a one-time $55M gross-to-net contract shift and a $12.9M retroactive revenue reduction from capitation true-ups; revenue declined $156M year-over-year.

• Adjusted EBITDA was $36.9M (7.6% margin), at the high end of guidance, with a favorable net impact of $0.4M from prior year development.

• Net loss margin widened to (14.9)% from (3.9)% year-over-year; GAAP net loss attributable to common shareholders: $(72.3)M.

• Cash and cash equivalents at quarter end were $246.5M, with $4.6M cash flow from operations.

• Net leverage ratio at quarter-end was 4.1x last 12-month adjusted EBITDA.

Outlook and guidance

• Full-year 2025 revenue guidance reiterated at $2.06B–$2.11B; adjusted EBITDA at $135M–$165M, assuming a 12% oncology trend for Q2–Q4.

• Q2 2025 revenue expected between $440M–$470M; adjusted EBITDA between $33M–$40M.

• Positive operating cash flow expected for the remainder of 2025, with year-end cash projected above $85M after liability management and asset purchases.

• Plans to deploy ~$35M in cash for capitalized software development in 2025.

• The company believes it has sufficient liquidity for at least the next twelve months.